Network Meta-Analysis Shows a Significant Advantage of Nilotinib Over Imatinib in Chronic Myeloid Leukemia
Published in Oncology
News · June 12, 2015
June 11, 2015 – Vienna, Austria – A comparison of different first-line treatment strategies for chronic myeloid leukemia in a network meta-analysis has shown a significant and relevant nilotinib advantage over standard imatinib 400 mg. This result, covering a patient population of 6314 patients, was reported at the 20th Congress of the European Hematology Society, from June 11 – 14, 2015.